Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial
Friday, January 8th, 2010Tekmira Pharmaceuticals Corporation (TSX:TKM) announced that it has concluded its ApoB SNALP Phase 1 human clinical trial. ApoB SNALP is designed to reduce the production of apolipoprotein B (ApoB), a protein produced in the liver that plays a central role in cholesterol metabolism. Tekmira enrolled a ...